RASP
Rasna Therapeutics, Inc. [RASP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RASP Stock Summary
Top 10 Correlated Stocks
RASP
In the News
RASP Financial details
Company Rating
-
Market Cap
6.02M
Income
-4.61M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-1.55
Forward P/E
-
PEG
-0.3
P/S
-
P/B
-3.01
P/C
-
P/FCF
-28.89
Quick Ratio
-
Current Ratio
0.02
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
50.98%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
100%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-10346%
ROE
209%
ROC
2.14%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0057-0.0319
52W High
-
52W Low
-
RSI
-
Rel Volume
2.22
Avg Volume
9
Volume
20
Perf Week
0%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
0%
-
-
-
-
Beta
-61.449
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.004
Change
0%
Company Profile
- Volume Average 9
- Market Capitalization 6.02M
- Employee 1
- CEO Ms. Keeren Shah
- Headquarters New York,NY,US
- IPO Date 2015-02-24
-
Website
https://www.rasna.com 
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It focuses on developing small molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.
